Targeting the defective airway macrophage function in chronic obstructive pulmonary disease (COPD): a new therapeutic approach

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1106377

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

COPD/emphysema is smoking-related, incurable and a leading cause of death. New treatments are urgently needed. We have reported that airway phagocyte dysfunction and inflammation in COPD or smoke-exposed mice can be improved by novel treatments including lectins and macrolide antibiotics. We now show that these effects can be greatly improved by low-dose aspirin. We will further investigate these therapies and also novel antibiotics that have been modified to lose their anti-bacterial activity

Funded Activity Details

Start Date: 01-01-2016

End Date: 01-01-2018

Funding Scheme: Project Grants

Funding Amount: $710,928.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Clinical Sciences not elsewhere classified

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

chronic obstructive pulmonary disease (COPD) | inflammation | lectins | smoking-related diseases | synergistic drug effect

Related Links